Results 141 to 150 of about 2,530 (165)

Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review. [PDF]

Medicine (Baltimore)
Jezani SN, Bastion MC.
europepmc   +1 more source

Investigation of the temporal distribution of anti-VEGF drugs in the retina and the correlation with the distribution of FcR isoforms. [PDF]

Genes Dis
He J, Jiang Y, Yang R, Lu Z, Li Z, Tu Z.
europepmc   +1 more source

Authors' response: "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group". [PDF]

Indian J Ophthalmol
Agarwal M, Muralidhar A, Chakraborty D, Shanmugam MP.   +3 more
europepmc   +1 more source

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study. [PDF]

Ophthalmol Ther
Ohnaka M, Sakurada Y, Hayashi A, Kadonosono K, Ohno H, Mori R, Matsumoto H, Nagamori I, Murata Y, Maio-Twofoot T, Karcher H, Takahashi H.   +11 more
europepmc   +1 more source

Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection. [PDF]

Korean J Ophthalmol
Kim MA, Choi SI, Kim JM, Oh HS, You YS, Lee WK, Kim SH, Kwon OW, Kim JY.   +8 more
europepmc   +1 more source

Short-term efficacy and safety of intravitreal brolucizumab in diabetic macular edema: A retrospective interventional study.

Oman J Ophthalmol
Mal W, Al-Abri M, Al Fadhil NA, Jaju S, Al-Riyami ASAS.   +4 more
europepmc   +1 more source

Comment on "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group". [PDF]

Indian J Ophthalmol
Sengupta S, Kelkar A, Jain HH.
europepmc   +1 more source

Novel anti-VEGF scFv antibodies with superior in vitro and in vivo activities. [PDF]

Sci Rep
Cakan-Akdogan G, Erez O, Ozer C, Onal E, Mert O, Gullu S, Arslan M, Avci ME, Inan M, Kalyoncu S.   +9 more
europepmc   +1 more source

Punctate Hyperfluorescence as a Favorable Predictive Factor for Treatment Response Following a Switch to Brolucizumab for Patients with Aflibercept-Refractory Neovascular Age-Related Macular Degeneration. [PDF]

J Clin Med
Kamao H, Goto K, Mizukawa K, Hiraki R, Miki A, Kimura S.   +5 more
europepmc   +1 more source

Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India. [PDF]

Indian J Ophthalmol
Ghosh AK, Chakraborty D, Sudhalkar A, Chawla R, Singh SR, Sahu AK, Venkatesh R, Raval V, Shah S, Preetha P, Bhavsar M, Patil S, Khadke I, Thorat A.   +13 more
europepmc   +1 more source